SCHEMBL27147102

SCHEMBL27147102

NC(=O)C1(Oc2ccccc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 2/20 0.41
CTNNB1 P35222 1/20 0.39
CTSK P43235 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP3A4 P08684 6/20 0.37
TSHR P16473 3/20 0.37
MAPK1 P28482 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.37
CYP2C19 P33261 2/20 0.37
MAPT P10636 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
POLB P06746 1/20 0.37
PARP1 P09874 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10208937 0.92 CTSK (0.45) PARP10CTNNB1CTSKMEN1KMT2A
SCHEMBL28170768 0.85 OPRM1 (0.43) KMT2ACYP3A4TSHRALDH1A1TDP1
SCHEMBL9569527 0.85 PARP10 (0.39) PARP10CTNNB1MEN1KMT2ACYP3A4
Hydrochloric Acid SCHEMBL28170771 0.84 OPRM1 (0.45) MEN1KMT2ACYP3A4TSHRALDH1A1
SCHEMBL27142106 0.83 AKR1C1 (0.41) CTSKMEN1KMT2ACYP3A4TSHR
SCHEMBL18322680 0.77 SMN1; SMN2 (0.37) CTSKMEN1KMT2ACYP3A4TSHR
SCHEMBL31117363 0.76 CTSK (0.44) CTSKCYP3A4TSHRMAPK1SMN1; SMN2
SCHEMBL19537446 0.76 CTSK (0.47) CTSKMEN1KMT2ACYP3A4TSHR
SCHEMBL31117786 0.76 CTSK (0.39) CTSKCYP3A4TSHRMAPK1SMN1; SMN2
SCHEMBL18469680 0.74 CTSK (0.49) CTSKMEN1KMT2AALDH1A1AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608823-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. Hoffmann-La Roche AG (CH) 2025-09-03 EP disclosed
US-20240199587-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-06-20 US disclosed
WO-2024088922-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) F. HOFFMANN-LA ROCHE AG (CH) 2024-05-02 WO disclosed
EP-4326714-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-02-28 EP disclosed
WO-2022223750-A1 HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199587-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP1A1, CYP4B1 PARP10 843/4885CTNNB1 751/4885CTSK 2643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.